ITBMed (private company)

See something wrong or missing? Let us know
Offices:Stockholm
Business model:B2B

ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.

Investors: we tracked 1 investor

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

values in USD

Investments 67M


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Companies with similar profile to ITBMed

Name Criteria
Sweden Cinclus Pharma
65%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • Total raised in a similar range: 10M+ USD
United Kingdom Causaly
65%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
  • Total raised in a similar range: 10M+ USD
Sweden iCellate
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
Denmark Octarine Bio
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
Sweden Pila Pharma
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
France PEP-Therapy
60%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • At least one angel investor: found 1
Denmark AFYX Therapeutics
55%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Netherlands Citryll
55%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Finland Nanoform Finland
55%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Denmark NMD Pharma
55%
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
Top